Trial suggests JAK1 inhibitor is superior to methotrexate for treatment of early rheumatoid arthritis

A selective Janus kinase inhibitor, upadacitinib, is superior to methotrexate in improving clinical outcomes in patients with rheumatoid arthritis,  a study has suggested.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research